Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Synta Pharmaceuticals Corp. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 0.44||$ 2.65|
|Low||$ 0.391||$ 0.15|
The current last sale of $0.4125 is 175.00% Higher thanthe 52 week low.
Company Description (as filed with the SEC)
Synta Pharmaceuticals Corp. is a company that has been historically focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. In October 2015, we announced the decision to terminate for futility the Phase 3 GALAXY-2 trial of our novel heat shock protein 90 (Hsp90) inhibitor, ganetespib, and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the study's Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel was unlikely to demonstrate a statistically significant improvement in overall survival, the primary endpoint of the study, compared to docetaxel alone. ... More ...
Where does SNTA fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$|
|Quarterly EPS Est:|